Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine.

Hanson IC, Antonelli TA, Sperling RS, Oleske JM, Cooper E, Culnane M, Fowler MG, Kalish LA, Lee SS, McSherry G, Mofenson L, Shapiro DE.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 15;20(5):463-7.

PMID:
10225228
2.

HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.

Welles SL, Pitt J, Colgrove R, McIntosh K, Chung PH, Colson A, Lockman S, Fowler MG, Hanson C, Landesman S, Moye J, Rich KC, Zorrilla C, Japour AJ.

AIDS. 2000 Feb 18;14(3):263-71.

PMID:
10716502
3.

Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants.

Sutthent R, Chokephaibulkit K, Piyasujabul D, Vanprapa N, Roogpisuthipong A, Chaisilwatana P.

J Clin Virol. 2002 Jul;25(1):47-56.

PMID:
12126721
4.

Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants.

Feiterna-Sperling C, Weizsaecker K, Bührer C, Casteleyn S, Loui A, Schmitz T, Wahn V, Obladen M.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):43-51.

PMID:
17356471
5.

Effectiveness of short-term and long-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission.

Bhoopat L, Khunamornpong S, Lerdsrimongkol P, Sirivatanapa P, Sethavanich S, Limtrakul A, Gomutbuthra V, Kajanavanich S, Thorner PS, Bhoopat T.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):545-50.

PMID:
16284530
6.

U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

Mofenson LM; Centers for Disease Control and Prevention, U.S. Public Health Service Task Force.

MMWR Recomm Rep. 2002 Nov 22;51(RR-18):1-38; quiz CE1-4.

7.

Effect of immediate neonatal zidovudine on prevention of vertical transmission of human immunodeficiency virus type 1.

Sirinavin S S, Phaupradit W, Taneepanichskul S, Atamasirikul K, Hetrakul P, Thakkinstian A, Panburana P.

Int J Infect Dis. 2000;4(3):148-52.

PMID:
11179918
8.

HIV infection and zidovudine use in childbearing women.

Sia J, Paul S, Martin RM, Cross H.

Pediatrics. 2004 Dec;114(6):e707-12. Epub 2004 Nov 15.

PMID:
15545619
9.

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.

Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J.

JAMA. 1999 Jan 13;281(2):151-7.

PMID:
9917118
10.

Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children.

Gaughan DM, Mofenson LM, Hughes MD, Seage GR 3rd, Ciupak GL, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Team.

Pediatrics. 2002 May;109(5):E74-4.

PMID:
11986480
11.

Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival.

Bardeguez AD, Shapiro DE, Mofenson LM, Coombs R, Frenkel LM, Fowler MG, Huang S, Sperling RS, Cunningham B, Gandia J, Maupin R, Zorrilla CD, Jones T, O'Sullivan MJ; Pediatrics AIDS Clinical Trials Group 288 Protocol Team.

J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):170-81.

PMID:
12571527
12.

Pediatric HIV clinical trials in the United States.

Landry S.

NIAID AIDS Agenda. 1997 Nov:3-4.

PMID:
11364921
13.

Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.

Carneiro M, Sanchéz A, Maneiro P, Angelosante W, Pérez C, Valleé M.

Placenta. 2001 Apr;22 Suppl A:S13-8.

PMID:
11312622
14.

Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.

Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.

Pediatr Infect Dis J. 2005 Jun;24(6):503-9.

PMID:
15933559
15.

In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.

Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean-Philippe P, Hughes MD, Seage GR 3rd.

AIDS. 2007 May 11;21(8):929-38.

PMID:
17457086
16.

Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.

Suksomboon N, Poolsup N, Ket-Aim S.

J Clin Pharm Ther. 2007 Jun;32(3):293-311. Review.

PMID:
17489882
17.
18.

Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy.

Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC.

Pediatr Infect Dis J. 2003 Sep;22(9):782-9.

PMID:
14506368
19.

A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.

Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, Nikodem C, Hall D, Gigliotti M, Robinson P, Boshoff L, Sullivan JL; South African Intrapartum Nevirapine Trial (SAINT) Investigators.

J Infect Dis. 2003 Mar 1;187(5):725-35. Epub 2003 Feb 24.

20.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

Items per page

Supplemental Content

Write to the Help Desk